Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership
Key Points
Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share.
The sale represented 2.19% of Raab's direct holdings at the time of the transaction.
Raab retains 395,001 stock options, which can be converted to Common Stock.
- 10 stocks we like better than Ardelyx ›
On Feb. 24, 2026, Ardelyx (NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 41,666 |
| Transaction value | $261,000 |
| Post-transaction shares (direct) | 1,836,153 |
| Post-transaction shares (indirect) | 25,364 |
| Post-transaction value (direct ownership) | ~$12M |
Transaction value based on SEC Form 4 weighted average purchase price ($6.25). Post-transaction value based on closing price of Feb. 24 ($6.56).
Key questions
- What is the context of the derivative activity in this filing?
This sale involved an option exercise of 20,833 shares prior, as mentioned in the SEC filing. - How did the transaction affect Raab’s overall ownership and liquidity profile?
Following the sale, Raab retains 1,836,153 shares directly and 25,364 shares indirectly.
Company overview
| Metric | Value |
|---|---|
| Price (as of Feb. 28, 2026) | $6.55 |
| Market capitalization | $1.61 billion |
| Revenue (TTM) | $407.32 million |
| Net Loss (TTM) | $61.60 |
Company snapshot
Ardelyx is a biotech company focused on innovative therapies for patients with gastrointestinal conditions and chronic kidney disease. Along with a strong client base in the U.S., it also partners with pharmaceutical entities in Canada, China, and Japan.
What this transaction means for investors
On Feb. 19, 2026, Ardelyx reported its Q4 earnings for fiscal year 2025, showing positive growth, including now having four consecutive years of revenue growth and a declining net loss. Its therapy treatment, IBSRELA, which is for patients with irritable bowel syndrome with constipation, has been highly successful. Its XPHOZAH treatment, which helps patients on dialysis manage chronic kidney disease, has also been a popular staple of the company.
On Feb. 24, the pharmaceutical company announced a multi-year partnership with the Ladies Professional Golf Association (LPGA), aiming to educate and mobilize women in health. Ardelyx, now an official corporate pharmaceutical marketing partner of the LPGA Tour, hopes to support women’s digestive health, including those with conditions such as irritable bowel syndrome and constipation.
The company’s stock price grew approximately 18% in 2025, and is currently up 15% this year. However, investors may want to monitor the growing speculation that Ardelyx could be acquired, as rumors suggest the Indian pharmaceutical company Zydus Lifesciences is exploring a majority stake in Ardelyx. This remains just rumors for now, but it is something to keep an eye on.
Should you buy stock in Ardelyx right now?
Before you buy stock in Ardelyx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ardelyx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 1, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool recommends Ardelyx. The Motley Fool has a disclosure policy.
Recommended Articles
